One of the reasons why hepatitis E is comparatively under-investigated is that a robust cell culture model for its study was only developed about three years ago in Bochum and Hanover.
Researchers are now able to use this model to investigate how the virus is able to infect cells, as outlined in the paper ’Epidermal growth factor receptor modulates hepatitis E virus entry in human hepatocytes’, published in Hepatology.
“We used drugs to suppress the activity of the EGFR protein in some cell lines at the time of virus entry,” explains first author Jil Alexandra Schrader. “In these cultures, we observed that there were significantly fewer infected cells.”
To cross-check this, the researchers used cell cultures in which the co-receptor was over-produced. In this case, more infections occurred than in untreated cells.
“This shows us that the protein EGFR is of great importance for the entry mechanism of the virus into the cells,” says Jil Schrader.
The part of the protein that is on the outside of the cells and to which ligands bind is important for the entry of the viruses. If it is missing, the viruses cannot penetrate the cell. Further investigations are needed to determine whether other players are required for the virus to infect cells or whether the receptor itself introduces the virus.
“For hepatitis C virus, for example, it is known that even more receptors are involved in the entry of the viruses into the cells,” explains Professor Eike Steinmann, head of the Department of Molecular and Medical Virology at Ruhr University Bochum. “This could also be the case with hepatitis E virus.”
The evidence that the EGF receptor is involved in infection is particularly interesting because there are already approved drugs that suppress its activity.
“These drugs are approved in Europe and the USA for certain cancers where the receptor is overactive and can cause uncontrolled cell growth,” explains Dr. Volker Kinast, virologist at the Carl von Ossietzky University Oldenburg. Further studies would have to show whether these agents could be a treatment option against hepatitis E.
The hepatitis E virus (HEV) is the main cause of acute viral hepatitis. Around 70,000 people die from the disease every year. After the first documented epidemic outbreak in 1955-1956, more than 50 years passed before researchers took a closer look at the issue.
Acute infections normally clear up on their own in patients with an intact immune system. In affected individuals with reduced or suppressed immune systems, such as organ transplant recipients or HIV-infected individuals, HEV can become chronic. HEV is also particularly dangerous for pregnant women.
No comments yet